Unichem USA recalls Cyclobenzaprine Hydrochloride Tablets due to mislabeling
The recall affects a specific lot of a widely distributed medication and poses potential health risks to consumers who may unknowingly take the wrong drug. This has a moderate impact on the company's reputation and potential liability.
The announcement discusses a voluntary recall of a product due to mislabeling, which indicates a potential quality control issue and could lead to negative consequences for consumers.
* Unichem Pharmaceuticals (USA), Inc. is voluntarily recalling one lot of Cyclobenzaprine Hydrochloride Tablets USP 10 mg due to mislabeling. * The Cyclobenzaprine 10mg label was placed on a bottle containing Meloxicam 7.5 mg tablets. * The affected lot number is GMML24026A with an expiry of Sept 2027 and NDC 29300-415-19, printed on 90-count bottles. * The product was distributed nationwide to distributors, retailers, and consumers. * Patients unknowingly taking Meloxicam face potential risks including cardiovascular, gastrointestinal, renal, anaphylaxis, and skin reactions. * Unichem Pharmaceuticals has not received any reports of adverse events related to this recall. * Consumers should return the medication to the pharmacy where they received their prescription. * Questions can be directed to Inmar at 1-877-840-5109 or rxrecalls@inmar.com.
What to do with a filing like this
Unichem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under regulatory filings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Unichem Laboratories Limited. Read the original for the full detail.